Early viral kinetics of telbivudine and entecavir: Results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B

Dong Jin Suh, Soon-Ho Um, Eva Herrmann, Ju Hyun Kim, Young Sok Lee, Heon Ju Lee, Myung Seok Lee, Youn Jae Lee, Weibin Bao, Patricia Lopez, Han Chu Lee, Claudio Avila, Stefan Zeuzem

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We characterized the early viral kinetic profiles of telbivudine and entecavir and the effects of these potent nucleoside analogs on hepatitis B virus (HBV) DNA and alanine aminotransferase levels in adults with hepatitis B e antigen-positive compensated chronic hepatitis B. Forty-four patients were enrolled in this open-label, parallel-group, multicenter study and randomized to receive telbivudine or entecavir for 12 weeks. Reductions in hepatitis B virus DNA and alanine aminotransferase levels from baseline to weeks 2, 4, 8, and 12 were assessed. Viral kinetic parameters, including viral clearance per day, loss of infected cells per day, and efficiency of inhibition of viral production, were estimated by using a biphasic mathematical model. Statistical analyses were limited to descriptive analyses. The 2 treatment groups achieved similar reductions in HBV DNA and alanine aminotransferase levels. Mean reductions in levels of hepatitis B virus DNA at week 12 were 6.6 ± 1.6 and 6.5 ± 1.5 log10 copies/ml for the telbivudine- and entecavir-treated patients, respectively. There were no significant differences between groups in values for mean viral clearance per day, mean loss of infected cells per day, or efficiency of blocking viral production. The safety profiles for both medications were favorable. During the first 12 weeks of treatment, telbivudine and entecavir demonstrated similar antiviral potencies, resulting in a rapid and profound suppression of serum hepatitis B virus DNA and reduction of alanine aminotransferase levels. No differences in the effects of these 2 agents on early viral kinetics were observed. Both medications were well tolerated.

Original languageEnglish
Pages (from-to)1242-1247
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume54
Issue number3
DOIs
Publication statusPublished - 2010 Mar 1

Fingerprint

Hepatitis B e Antigens
Chronic Hepatitis B
Hepatitis B virus
Alanine Transaminase
DNA
Nucleosides
Multicenter Studies
Antiviral Agents
Theoretical Models
entecavir
telbivudine
Safety
Therapeutics
Serum

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Early viral kinetics of telbivudine and entecavir : Results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. / Suh, Dong Jin; Um, Soon-Ho; Herrmann, Eva; Kim, Ju Hyun; Lee, Young Sok; Lee, Heon Ju; Lee, Myung Seok; Lee, Youn Jae; Bao, Weibin; Lopez, Patricia; Lee, Han Chu; Avila, Claudio; Zeuzem, Stefan.

In: Antimicrobial Agents and Chemotherapy, Vol. 54, No. 3, 01.03.2010, p. 1242-1247.

Research output: Contribution to journalArticle

Suh, DJ, Um, S-H, Herrmann, E, Kim, JH, Lee, YS, Lee, HJ, Lee, MS, Lee, YJ, Bao, W, Lopez, P, Lee, HC, Avila, C & Zeuzem, S 2010, 'Early viral kinetics of telbivudine and entecavir: Results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B', Antimicrobial Agents and Chemotherapy, vol. 54, no. 3, pp. 1242-1247. https://doi.org/10.1128/AAC.01163-09
Suh, Dong Jin ; Um, Soon-Ho ; Herrmann, Eva ; Kim, Ju Hyun ; Lee, Young Sok ; Lee, Heon Ju ; Lee, Myung Seok ; Lee, Youn Jae ; Bao, Weibin ; Lopez, Patricia ; Lee, Han Chu ; Avila, Claudio ; Zeuzem, Stefan. / Early viral kinetics of telbivudine and entecavir : Results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. In: Antimicrobial Agents and Chemotherapy. 2010 ; Vol. 54, No. 3. pp. 1242-1247.
@article{e8f277a721b64e4eba62b0c782d4cd74,
title = "Early viral kinetics of telbivudine and entecavir: Results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B",
abstract = "We characterized the early viral kinetic profiles of telbivudine and entecavir and the effects of these potent nucleoside analogs on hepatitis B virus (HBV) DNA and alanine aminotransferase levels in adults with hepatitis B e antigen-positive compensated chronic hepatitis B. Forty-four patients were enrolled in this open-label, parallel-group, multicenter study and randomized to receive telbivudine or entecavir for 12 weeks. Reductions in hepatitis B virus DNA and alanine aminotransferase levels from baseline to weeks 2, 4, 8, and 12 were assessed. Viral kinetic parameters, including viral clearance per day, loss of infected cells per day, and efficiency of inhibition of viral production, were estimated by using a biphasic mathematical model. Statistical analyses were limited to descriptive analyses. The 2 treatment groups achieved similar reductions in HBV DNA and alanine aminotransferase levels. Mean reductions in levels of hepatitis B virus DNA at week 12 were 6.6 ± 1.6 and 6.5 ± 1.5 log10 copies/ml for the telbivudine- and entecavir-treated patients, respectively. There were no significant differences between groups in values for mean viral clearance per day, mean loss of infected cells per day, or efficiency of blocking viral production. The safety profiles for both medications were favorable. During the first 12 weeks of treatment, telbivudine and entecavir demonstrated similar antiviral potencies, resulting in a rapid and profound suppression of serum hepatitis B virus DNA and reduction of alanine aminotransferase levels. No differences in the effects of these 2 agents on early viral kinetics were observed. Both medications were well tolerated.",
author = "Suh, {Dong Jin} and Soon-Ho Um and Eva Herrmann and Kim, {Ju Hyun} and Lee, {Young Sok} and Lee, {Heon Ju} and Lee, {Myung Seok} and Lee, {Youn Jae} and Weibin Bao and Patricia Lopez and Lee, {Han Chu} and Claudio Avila and Stefan Zeuzem",
year = "2010",
month = "3",
day = "1",
doi = "10.1128/AAC.01163-09",
language = "English",
volume = "54",
pages = "1242--1247",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Early viral kinetics of telbivudine and entecavir

T2 - Results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B

AU - Suh, Dong Jin

AU - Um, Soon-Ho

AU - Herrmann, Eva

AU - Kim, Ju Hyun

AU - Lee, Young Sok

AU - Lee, Heon Ju

AU - Lee, Myung Seok

AU - Lee, Youn Jae

AU - Bao, Weibin

AU - Lopez, Patricia

AU - Lee, Han Chu

AU - Avila, Claudio

AU - Zeuzem, Stefan

PY - 2010/3/1

Y1 - 2010/3/1

N2 - We characterized the early viral kinetic profiles of telbivudine and entecavir and the effects of these potent nucleoside analogs on hepatitis B virus (HBV) DNA and alanine aminotransferase levels in adults with hepatitis B e antigen-positive compensated chronic hepatitis B. Forty-four patients were enrolled in this open-label, parallel-group, multicenter study and randomized to receive telbivudine or entecavir for 12 weeks. Reductions in hepatitis B virus DNA and alanine aminotransferase levels from baseline to weeks 2, 4, 8, and 12 were assessed. Viral kinetic parameters, including viral clearance per day, loss of infected cells per day, and efficiency of inhibition of viral production, were estimated by using a biphasic mathematical model. Statistical analyses were limited to descriptive analyses. The 2 treatment groups achieved similar reductions in HBV DNA and alanine aminotransferase levels. Mean reductions in levels of hepatitis B virus DNA at week 12 were 6.6 ± 1.6 and 6.5 ± 1.5 log10 copies/ml for the telbivudine- and entecavir-treated patients, respectively. There were no significant differences between groups in values for mean viral clearance per day, mean loss of infected cells per day, or efficiency of blocking viral production. The safety profiles for both medications were favorable. During the first 12 weeks of treatment, telbivudine and entecavir demonstrated similar antiviral potencies, resulting in a rapid and profound suppression of serum hepatitis B virus DNA and reduction of alanine aminotransferase levels. No differences in the effects of these 2 agents on early viral kinetics were observed. Both medications were well tolerated.

AB - We characterized the early viral kinetic profiles of telbivudine and entecavir and the effects of these potent nucleoside analogs on hepatitis B virus (HBV) DNA and alanine aminotransferase levels in adults with hepatitis B e antigen-positive compensated chronic hepatitis B. Forty-four patients were enrolled in this open-label, parallel-group, multicenter study and randomized to receive telbivudine or entecavir for 12 weeks. Reductions in hepatitis B virus DNA and alanine aminotransferase levels from baseline to weeks 2, 4, 8, and 12 were assessed. Viral kinetic parameters, including viral clearance per day, loss of infected cells per day, and efficiency of inhibition of viral production, were estimated by using a biphasic mathematical model. Statistical analyses were limited to descriptive analyses. The 2 treatment groups achieved similar reductions in HBV DNA and alanine aminotransferase levels. Mean reductions in levels of hepatitis B virus DNA at week 12 were 6.6 ± 1.6 and 6.5 ± 1.5 log10 copies/ml for the telbivudine- and entecavir-treated patients, respectively. There were no significant differences between groups in values for mean viral clearance per day, mean loss of infected cells per day, or efficiency of blocking viral production. The safety profiles for both medications were favorable. During the first 12 weeks of treatment, telbivudine and entecavir demonstrated similar antiviral potencies, resulting in a rapid and profound suppression of serum hepatitis B virus DNA and reduction of alanine aminotransferase levels. No differences in the effects of these 2 agents on early viral kinetics were observed. Both medications were well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=77149167555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77149167555&partnerID=8YFLogxK

U2 - 10.1128/AAC.01163-09

DO - 10.1128/AAC.01163-09

M3 - Article

C2 - 20028815

AN - SCOPUS:77149167555

VL - 54

SP - 1242

EP - 1247

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -